POCT PT INR — Is it adequate for patient care? A comparison of the Roche Coaguchek XS vs. Stago Star vs. Siemens BCS in patients routinely seen in an anticoagulation clinic

Wendy S. Baker, Kathleen J. Albright, Megan Berman, Heidi Spratt, Peggy A. Mann, Jaime Unabia, John R. Petersen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background In this study we examined the difference in patient INR values as measured by the POCT CoaguChek XS device and central laboratory Stago Evolution and Siemens BCS XP analyzers. Methods This study composed of 100 warfarin therapy patients and 20 coagulation normal subjects, showed that the difference between the POCT and clinical laboratory values increased with increasing INR and was exacerbated by the use of different thromboplastin reagents by the POCT and central lab. Results The CoaguChek XS and on-site Stago analyzers which used human recombinant (ISI = 1.01) and rabbit brain thromboplastin (ISI = 1.25), respectively, showed reasonable agreement for INR < 3.0 (k = 0.62) but significant difference for INR ≥ 3.0 (k = 0.10). In contrast, the CoaguChek XS and Siemens BCS XP, which both employed human recombinant thromboplastin (BCS ISI = 1.02), showed greater agreement for the complete range INR values (INR < 3.0 k = 0.84; INR ≥ 3.0 k = 0.70). ECAA Poller calibrant data showed the automated instruments were performing as expected, indicating that ISI calibrations were correct but insufficient to standardize the INR values for the different thromboplastin methods across the full range of measured INRs. Central lab verification of POCT INR > 5.0 with the Stago Evolution prevented adverse treatment events for the warfarin therapy patients in the six months preceding and following this investigation.

Original languageEnglish (US)
Pages (from-to)139-145
Number of pages7
JournalClinica Chimica Acta
Volume472
DOIs
StatePublished - Sep 1 2017

Fingerprint

International Normalized Ratio
Thromboplastin
Warfarin
Stars
Patient Care
Clinical laboratories
Coagulation
Brain
Therapeutics
Rabbits
Equipment and Supplies

Keywords

  • Anticoagulation
  • CoaguChek XS
  • INR
  • International normalized ratio
  • POCT
  • Point of care testing

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

POCT PT INR — Is it adequate for patient care? A comparison of the Roche Coaguchek XS vs. Stago Star vs. Siemens BCS in patients routinely seen in an anticoagulation clinic. / Baker, Wendy S.; Albright, Kathleen J.; Berman, Megan; Spratt, Heidi; Mann, Peggy A.; Unabia, Jaime; Petersen, John R.

In: Clinica Chimica Acta, Vol. 472, 01.09.2017, p. 139-145.

Research output: Contribution to journalArticle

Baker, Wendy S. ; Albright, Kathleen J. ; Berman, Megan ; Spratt, Heidi ; Mann, Peggy A. ; Unabia, Jaime ; Petersen, John R. / POCT PT INR — Is it adequate for patient care? A comparison of the Roche Coaguchek XS vs. Stago Star vs. Siemens BCS in patients routinely seen in an anticoagulation clinic. In: Clinica Chimica Acta. 2017 ; Vol. 472. pp. 139-145.
@article{4906f6bf33db4ef08bb6c0a13066dc3d,
title = "POCT PT INR — Is it adequate for patient care? A comparison of the Roche Coaguchek XS vs. Stago Star vs. Siemens BCS in patients routinely seen in an anticoagulation clinic",
abstract = "Background In this study we examined the difference in patient INR values as measured by the POCT CoaguChek XS device and central laboratory Stago Evolution and Siemens BCS XP analyzers. Methods This study composed of 100 warfarin therapy patients and 20 coagulation normal subjects, showed that the difference between the POCT and clinical laboratory values increased with increasing INR and was exacerbated by the use of different thromboplastin reagents by the POCT and central lab. Results The CoaguChek XS and on-site Stago analyzers which used human recombinant (ISI = 1.01) and rabbit brain thromboplastin (ISI = 1.25), respectively, showed reasonable agreement for INR < 3.0 (k = 0.62) but significant difference for INR ≥ 3.0 (k = 0.10). In contrast, the CoaguChek XS and Siemens BCS XP, which both employed human recombinant thromboplastin (BCS ISI = 1.02), showed greater agreement for the complete range INR values (INR < 3.0 k = 0.84; INR ≥ 3.0 k = 0.70). ECAA Poller calibrant data showed the automated instruments were performing as expected, indicating that ISI calibrations were correct but insufficient to standardize the INR values for the different thromboplastin methods across the full range of measured INRs. Central lab verification of POCT INR > 5.0 with the Stago Evolution prevented adverse treatment events for the warfarin therapy patients in the six months preceding and following this investigation.",
keywords = "Anticoagulation, CoaguChek XS, INR, International normalized ratio, POCT, Point of care testing",
author = "Baker, {Wendy S.} and Albright, {Kathleen J.} and Megan Berman and Heidi Spratt and Mann, {Peggy A.} and Jaime Unabia and Petersen, {John R.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.cca.2017.07.027",
language = "English (US)",
volume = "472",
pages = "139--145",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - POCT PT INR — Is it adequate for patient care? A comparison of the Roche Coaguchek XS vs. Stago Star vs. Siemens BCS in patients routinely seen in an anticoagulation clinic

AU - Baker, Wendy S.

AU - Albright, Kathleen J.

AU - Berman, Megan

AU - Spratt, Heidi

AU - Mann, Peggy A.

AU - Unabia, Jaime

AU - Petersen, John R.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background In this study we examined the difference in patient INR values as measured by the POCT CoaguChek XS device and central laboratory Stago Evolution and Siemens BCS XP analyzers. Methods This study composed of 100 warfarin therapy patients and 20 coagulation normal subjects, showed that the difference between the POCT and clinical laboratory values increased with increasing INR and was exacerbated by the use of different thromboplastin reagents by the POCT and central lab. Results The CoaguChek XS and on-site Stago analyzers which used human recombinant (ISI = 1.01) and rabbit brain thromboplastin (ISI = 1.25), respectively, showed reasonable agreement for INR < 3.0 (k = 0.62) but significant difference for INR ≥ 3.0 (k = 0.10). In contrast, the CoaguChek XS and Siemens BCS XP, which both employed human recombinant thromboplastin (BCS ISI = 1.02), showed greater agreement for the complete range INR values (INR < 3.0 k = 0.84; INR ≥ 3.0 k = 0.70). ECAA Poller calibrant data showed the automated instruments were performing as expected, indicating that ISI calibrations were correct but insufficient to standardize the INR values for the different thromboplastin methods across the full range of measured INRs. Central lab verification of POCT INR > 5.0 with the Stago Evolution prevented adverse treatment events for the warfarin therapy patients in the six months preceding and following this investigation.

AB - Background In this study we examined the difference in patient INR values as measured by the POCT CoaguChek XS device and central laboratory Stago Evolution and Siemens BCS XP analyzers. Methods This study composed of 100 warfarin therapy patients and 20 coagulation normal subjects, showed that the difference between the POCT and clinical laboratory values increased with increasing INR and was exacerbated by the use of different thromboplastin reagents by the POCT and central lab. Results The CoaguChek XS and on-site Stago analyzers which used human recombinant (ISI = 1.01) and rabbit brain thromboplastin (ISI = 1.25), respectively, showed reasonable agreement for INR < 3.0 (k = 0.62) but significant difference for INR ≥ 3.0 (k = 0.10). In contrast, the CoaguChek XS and Siemens BCS XP, which both employed human recombinant thromboplastin (BCS ISI = 1.02), showed greater agreement for the complete range INR values (INR < 3.0 k = 0.84; INR ≥ 3.0 k = 0.70). ECAA Poller calibrant data showed the automated instruments were performing as expected, indicating that ISI calibrations were correct but insufficient to standardize the INR values for the different thromboplastin methods across the full range of measured INRs. Central lab verification of POCT INR > 5.0 with the Stago Evolution prevented adverse treatment events for the warfarin therapy patients in the six months preceding and following this investigation.

KW - Anticoagulation

KW - CoaguChek XS

KW - INR

KW - International normalized ratio

KW - POCT

KW - Point of care testing

UR - http://www.scopus.com/inward/record.url?scp=85026860042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026860042&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2017.07.027

DO - 10.1016/j.cca.2017.07.027

M3 - Article

VL - 472

SP - 139

EP - 145

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -